Brain Natriuretic Peptide in Decompensation of Liver Cirrhosis
in Non-cardiac Patients

J 2009

Brain Natriuretic Peptide in Decompensation of Liver Cirrhosis in Non-cardiac Patients

RADVAN, Martin, Petr SVOBODA, Jana RADVANOVA, Josef STUMAR, Peter SCHEER et. al.

Základní údaje

Originální název

Brain Natriuretic Peptide in Decompensation of Liver Cirrhosis in Non-cardiac Patients

Název česky

BNP u pacientů s dekompenzovanou jaterní cirhózou bez kardiologického onemocnění

Autoři

RADVAN, Martin, Petr SVOBODA, Jana RADVANOVA, Josef STUMAR a Peter SCHEER

Vydání

Hepato-gastroenterology, 2009, 0172-6390

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30000 3. Medical and Health Sciences

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 0.669

Organizační jednotka

Lékařská fakulta

UT WoS

000265203100038

Klíčová slova česky

mozkový natriuretický hormon; cirhóza; ascites; kardiomyopatie

Klíčová slova anglicky

Brain natriuretic; peptides; cirrhosis; ascites; cardiomyopathy

Příznaky

Mezinárodní význam

Změněno: 20. 4. 2012 11:02, Mgr. Michal Petr

Anotace

ORIG CZ

V originále

Brain natriuretic peptide is recently widely used as a diagnostic and prognostic marker of heart failure. Plasma levels of this peptide are elevated in other, non-cardiac conditions as well, among others in liver cirrhosis, especially presenting with fluid retention and, - ascites. Methods: Circulating levels of BNP was determined in 25 non-cardiac patients, 20 men, 5 women admitted at our medicine department from March 2006 to September 2007 with decompensate ascitic liver cirrhosis. Severity of disease was measured by Child and MELD (Model of End Stage of Liver Disease) score. Results: Plasma BNP was increased in our patients (range 21-1078pg/ml) and significantly correlated with the severity of liver failure assigned as Child's classification (r=0.51; p=0.009) and MELD score (r=0.56; p=0.003) as well as with the glomerular filtration rate (r=-0.62; p=0.0009). Four patients with initial BNP >600 ng/L died, while all 21 patients with BNP <600 ng/L survived (p=0.0019). Conclusion: B-type natriuretic peptide in plasma correlated significantly with the severity of liver disease in cirrhotic patients. High plasma BNP seems to be a good negative prognostic factor of the death in cirrhosis.

Česky

B typ BNP v plazmě byl statisticky významně závislý na závažnosti onemocnění u pacientů s jaterní cirhózou. Vysoká hladina BNP zřejmě bude dobrý prognostický faktor pro úmrtí u cirhotiků

Citovat

RADVAN, Martin, Petr SVOBODA, Jana RADVANOVA, Josef STUMAR a Peter SCHEER. Brain Natriuretic Peptide in Decompensation of Liver Cirrhosis in Non-cardiac Patients. Hepato-gastroenterology. 2009, roč. 56, č. 89, s. 181-185. ISSN 0172-6390.

@article{838323,
   author = {Radvan, Martin and Svoboda, Petr and Radvanova, Jana and Stumar, Josef and Scheer, Peter and Svoboda, Petr and Radvanová, Jana and Štumar, Josef and Scheer, Peter},
   article_number = {89},
   keywords = {Brain natriuretic; peptides; cirrhosis; ascites; cardiomyopathy},
   language = {eng},
   issn = {0172-6390},
   journal = {Hepato-gastroenterology},
   title = {Brain Natriuretic Peptide in Decompensation of Liver Cirrhosis in Non-cardiac Patients},
   volume = {56},
   year = {2009}
}

TY  - JOUR
ID  - 838323
AU  - Radvan, Martin - Svoboda, Petr - Radvanova, Jana - Stumar, Josef - Scheer, Peter - Svoboda, Petr - Radvanová, Jana - Štumar, Josef - Scheer, Peter
PY  - 2009
TI  - Brain Natriuretic Peptide in Decompensation of Liver Cirrhosis in Non-cardiac Patients
JF  - Hepato-gastroenterology
VL  - 56
IS  - 89
SP  - 181-185
EP  - 181-185
SN  - 01726390
KW  - Brain natriuretic
KW  - peptides
KW  - cirrhosis
KW  - ascites
KW  - cardiomyopathy
N2  - Brain natriuretic peptide is recently widely used as a diagnostic and prognostic marker of heart failure. Plasma levels of this peptide are elevated in other, non-cardiac conditions as well, among others in liver cirrhosis, especially presenting with fluid retention and, - ascites. Methods: Circulating levels of BNP was determined in 25 non-cardiac patients, 20 men, 5 women admitted at our medicine department from March 2006 to September 2007 with decompensate ascitic liver cirrhosis. Severity of disease was measured by Child and MELD (Model of End Stage of Liver Disease) score. Results: Plasma BNP was increased in our patients (range 21-1078pg/ml) and significantly correlated with the severity of liver failure assigned as Child's classification (r=0.51; p=0.009) and MELD score (r=0.56; p=0.003) as well as with the glomerular filtration rate (r=-0.62; p=0.0009). Four patients with initial BNP >600 ng/L died, while all 21 patients with BNP <600 ng/L survived (p=0.0019). Conclusion: B-type natriuretic peptide in plasma correlated significantly with the severity of liver disease in cirrhotic patients. High plasma BNP seems to be a good negative prognostic factor of the death in cirrhosis.
ER  -

RADVAN, Martin, Petr SVOBODA, Jana RADVANOVA, Josef STUMAR a Peter SCHEER. Brain Natriuretic Peptide in Decompensation of Liver Cirrhosis in Non-cardiac Patients. \textit{Hepato-gastroenterology}. 2009, roč.~56, č.~89, s.~181-185. ISSN~0172-6390.

Podrobný výpis o publikaci